Introduction

According to the World Health Organization, the most frequent cancer diagnosis and the main cause of cancer mortality in women globally is breast cancer.1 Traditional breast cancer therapy (BCT) has been the gold standard of care for the past 20 years, and it has significantly improved patient outcomes.2 Nonetheless, inability to take into account the distinct features of every patient’s cancer typically led to ineffective, nontargeted treatment with negative side effects that include toxicity, a reduced quality of life, and, in certain cases, a subsequent delay in the detection of progression.2–4 The lack of consideration for each patient’s tumor characteristics hinders the advancement of more effective treatments, as clinical trials and drug development efforts may not accurately represent treatment efficacy.3,5 Since breast cancer is described as a heterogeneous disease that affects a spectrum of patients from different age groups, cultures, religions, ages, health conditions, and genders, there is a need to deliver the treatment tailored to their characteristics.2,3 Although patients may share similar characteristics, each individual patient should have a respective personalized treatment.2 Evolution in precision medicine and personalized treatments aims to address some of the challenges associated with traditional approaches and offer more personalized effective options for breast cancer patients.6,7 Thus, today, BCT is shifting towards more personalized approaches that enhance patient experience considering diverse characteristics and evolving conditions.3,5 The authors interpret this shift as a transition towards agility.

Multidisciplinary research provided knowledge returns to people, motivated communities, and enhanced environmental consequences.8 It has shown that there is a more complex and larger collaborative world beyond their single discipline.8 The fields of software engineering and BCT may complement one another in a number of ways to advance BCT and research. High-quality useful software products are generated as outputs from good, designed software development processes. Two well-known development approaches are applied in the field of software engineering and in BCT: traditional and agile.9 The traditional, namely, the waterfall, development process is described as a linear structured approach. Each phase must be completed before moving on to the next, and there is little to no backtracking or iteration between phases.9 Incorporating user feedback into a project is frequently left until the latter phases.9 The result may be that the finished product falls short of user demands or expectations.9 This is because clients may modify their requirements after seeing functional software because they are unsure of what they originally wanted, which results in more costly redesign, rebuilding, and retesting. Traditional software development approach has negative characteristics including its low user involvement, limited flexibility, late detection of errors, long and delayed time-to-market cycle, and high cost.9 It is too rigid, thus, too risky.

In February 2001, the Agile Manifesto was created to promote agile practices in software development and other fields through four values and 12 principles.10 Agile is a mindset, considering that its four values and 12 principles are not firm rules to follow. The agile mindset has changed how software products are developed.11,12 Wherever user-centered experience and design is considered in the work of an agile team, value delivery to customer is enhanced.13 Agility has been adopted in the healthcare industry to transform traditional care delivery into personalized treatment that is patient-centric where the patient is involved in decision-making, enhances learning and continuous improvement, promotes individuals cooperation, enhances innovation, and flexibility of health service design.14–20

The founders of agile principles have prioritized individuals collaboration since they are the ones who will determine the success or failure of a software project, over the techniques, tools, or technology employed. Similarly, in the cancer treatment process, the patient is at the primary focus of care. This appears by developing a personalized treatment plan that takes the patient’s preferences, situation, and values into account and by working with their family to create precise and comprehensive strategies.21 However, many barriers occur while planning for treatment. These are related to the concurrent illness, patient’s health literacy, and emotional state.21 Overcoming these barriers could be through adopting an agile mindset.21–23

In this article, we aim to identify BCT agile principles that are adopted from the software engineering field. The translation of agility values is not in the scope of this work. Also, to investigate whether breast cancer therapy actions are carried out in an agile manner or if they still adhere to traditional forms in some aspects. This is crucial in order to inform decision-making and multidisciplinary collaboration, to respond to continuous changes and adjustments regarding the treatment plan, and to personalize care, increase treatment efficacy, innovate through clinical trials, and comprehend and reflect on possible treatment outcomes. Together, patients and breast cancer care professionals collaborate to choose the best course of action for each unique patient, increasing the opportunity for a good treatment outcome and a higher standard of living in terms of quality of life.

Material and Methods presents our conducted research methodology. This section presents a walkthrough validation in literature of the 12 agile breast cancer treatment principles, as identified by the domain expert. Results presents the results. Discussion is carried out in Discussion. Finally, we conclude the work in Conclusion.

Material and Methods

In this section, we present a multidisciplinary research methodology designed to identify the BCT agility principles that are adopted and adapted from the software engineering field. During the research, the authors validate whether the BCT identified principles conform to agility. This can bring several benefits to the research community and BCT process, professionals, and patients. The research methodology is shown in Figure 1.

Figure 1 Research Methodology.

The designed methodology encourages scientists to actively participate from different disciplines in the multidisciplinary process of problem-solving to produce outcomes and contribute to knowledge that can directly impact healthcare community. This contributes to enriching the aimed outcome and to bridge the gap between different disciplines.

The process directs the researcher through six phases of a structured overlapping process focusing on identifying and validating BCT agile principles. The six phases are identifying the research problem and motivation, proposing solution that addresses the problem, eliciting BCT agile principles from oncologists, validating the identified BCT agile principles through reporting literature, validating the BCT agile principles through domain experts, and, finally, communicating and disseminating knowledge. Iterations within phases are permitted for refinement needs.

Phase 1: Identifying Research Problem and Motivation

Breast cancer treatment lifecycle involves complex and dynamic actions and requirements. Well-defined principles for BCT may be necessary to ensure agility, efficiency, personalization, safe progress, and successful outcomes with minimum side effects. According to a literature review and to our knowledge, there is a lack of validated identification of BCT agile principles, although BCT professionals strive to adhere to agility as reported in the literature. For instance, personalized medicine is widely adopted in BCT and conforms to agility in one way or another.3 In the field of software engineering, agile principles have shown promise in enhancing productivity, adaptability, customer satisfaction, and collaboration in software development. This has motivated the authors to integrate knowledge and expertise from software engineering discipline that can lead to enhancing knowledge exchange that contribute to the BCT field.

Herein, we describe our research motivation. Multidisciplinary research efforts in cancer care can lead to better patient care, improved treatment options, and disease prevention strategies. Further, this work paves the way for future collaboration of researchers and individuals from academia, software engineering and technology, economics, healthcare, and government.8 Nevertheless, this multidisciplinary research can lead to personal and professional growth for the individuals involved.8

It is essential for patients to have open, transparent, and personalized communication with their care team professionals and health providers about their treatment approach and whether it is agile or not. Patients are empowered when they are aware of how BCT is delivered, particularly if agile mindsets are leading the journey. This encourages them to take an active role in making decisions about their care, asking pertinent questions, and advocating for appropriate treatment options that meet their individual needs and circumstances. Having an initial manifesto for agile BCT in means of validated principles would pave the way to lead to the identification of more personalized and flexible BCT policies, procedures, and protocols. Moreover, specifying quality assurance processes that indicate the extent of conformance to agility is another motivation to bring to BCT policy-makers. Hence, this motivates healthcare organizations to improve their care delivery considering higher patient satisfaction.

Phase 2: Proposing Solution

Based on the identified research problem and associated motivation, the authors seek to identify BCT agile principles. The twelve BCT agile principles are adopted and adapted from the software engineering field. Also, the authors aim to investigate their conformance to agility in BCT context through a walkthrough validation in literature by referencing respective works for each identified BCT agile principle.

Phase 3: Eliciting Twelve BCT Agile Principles from Oncologist

Through three interview elicitation sessions with a BC oncologist, the 12 agile principles of software engineering were reviewed and rearticulated into language that is tailored to BCT practitioners. To validate these identified BCT agility principles, each of them is presented in the next phase and discussed through work reported from the literature. In the discussion below, the reader can observe reflection, based on the literature, that describes the extent of the agility conformance of the proposed identified BCT agile principle. The output here is the 12 identified BCT agility principles as follows:

Principle 1: Our highest priority is to satisfy the patient and family through early and continuous delivery of effective safe treatment.

Principle 2: Welcome changing requirements, even late in treatment lifecycle. Agile treatment cycles harness change for the patient’s benefit regarding cure, treatment side effects, and quality of life.

Principle 3: Deliver effective and safe treatment frequently with a preference for short timescales without contradicting the principles of effective and safe treatment.

Principle 4: Patients, their families, and treatment team must work together regularly throughout the treatment lifecycle.

Principle 5: Develop cancer treatment plans and solutions around motivated individuals. Give them the environment and support they need and trust them to get the job done.

Principle 6: The most efficient and effective method of conveying information to patients and within treatment teams is a combination of face-to-face conversation, digital tools, and online community groups.

Principle 7: Overall patient survival, QoL, disease-free survival, and progression-free survival are the ultimate measures of progress.

Principle 8: Cancer care institutional policies, breast cancer team, and patients should sustain a constant rhythm in breast cancer treatment life cycle.

Principle 9: Continuous attention to technical excellence and appropriate design of BCT plan according to available data enhances agility.

Principle 10: It is essential to meet patient needs through a simple treatment plan.

Principle 11: The best breast cancer treatment plans, treatment requirements, and tests emerge from self-organizing teams.

Principle 12: At regular intervals, the MD treatment team reflects on how to become more effective, and then tunes and adjusts its behavior accordingly.

Phase 4: Validating BCT Agile Principles Through Literature Walkthrough

In this phase, the authors present work reported from literature for each identified BCT agile principle to validate its extent of conformance to agility. Each principle is discussed below with work referenced from literature.

The First Principle

The first software engineering agile principle states that “our highest priority is to satisfy the customer through early and continuous delivery of valuable software”.10 As the primary focus of the agile mindset is the customer, customer satisfaction is considered the ultimate measure of success.10 Instead of waiting for the entire product to be developed, the team works to deliver it in an incremental manner to investigate if it meets their needs and expectations and promptly respond accordingly if any improvements are required. Incremental delivery allows customers to feel tangible benefits of the products and, thus, increases satisfaction. This also enables a quicker response to changing market demands and customer needs.10 This principle can be translated into BCT language as follows: “our highest priority is to satisfy the patient and family through early and continuous delivery of effective safe treatment”.

In BCT, a patient and the family are also the focus. The treatment delivery pattern is incremental and observed through the patient’s continuous visits, where visit feedback is looped into the overall cycle to improve the next treatment cycle in the next visit. Patient satisfaction could be addressed through Shared Decision-Making (SDM), where professionals strive to implicate their preferences in the treatment plan.24–26 In SDM, patients and others participate in providing valuable information that supports the complex therapy process.25 By doing this, the mismatch between the information people require and what is provided is reduced.25 Incorporating a patient into the SDM process allows tailoring the treatment plan to the patient’s preferences, which improves patient satisfaction and makes the treatment process more patient-centered.26

Regarding the early and continuous treatment delivery aspects of this principle, studies reported higher survival rate with early detection through screening and timely diagnosis, which are fundamental to an effective BCT.27,28 Research consistently shows that early-stage breast cancer has a higher likelihood of successful treatment and improved survival rates.27,28 For example, widespread screening program participation and compliance in western nations has resulted in early detection and higher survival rates for women.28 With an early focus on quality of life, ongoing specific strategies are needed to manage the long-term effects of breast cancer therapies as survival rates and the number of patients who are cured increase.27 It is essential to provide uninterrupted therapy to ensure optimal outcomes, minimize the risk of disease progression, and enhance patients’ quality of life. This should not be carried out without considering the management of the side effects according to the patient’s desires and characteristics.29

There is no commonly agreed definition of effective, safe BCT. Timely and continuous delivery of BCT is crucial for improving patient outcomes and ensuring their safety. Early diagnosis, followed by a well-structured treatment plan delivered without delays, significantly contributes to the effectiveness and safety of BCT.30 Moreover, early diagnosis allows for the development of a comprehensive and personalized treatment plan. Tailoring treatment to an individual patient’s specific cancer characteristics contributes to the effectiveness and safety of therapy.31 Initiating treatment promptly after diagnosis helps prevent the progression of the disease. Delayed treatment may lead to the advancement of the cancer, which can decrease treatment effectiveness and pose greater risks to the patient.32 Effective SDM contributes to effective and safe BCT and improved quality of life requirements, where patients are fully informed about all treatment tradeoffs and risks when participating in decision-making.25 Finally, continuous and consistent treatment management reduces the risk of complications. Careful monitoring and adherence to treatment protocols ensure that patients receive the necessary interventions to manage side effects and complications promptly, leading to increasing BCT safety and effectiveness.33

The Second Principle

In software engineering, this principle states that “Welcome changing requirements, even late in development. Agile processes harness change for the customer’s competitive advantage”.10 An agile team understands that changes are always expected to happen at any point of the project lifecycle.10 Therefore, the team remains open and responsive to changes that may entail emerging customer needs, market conditions, or even new trends and insights.10 This principle can be translated into BCT language as:

Welcome changing requirements, even late in treatment lifecycle. Agile treatment cycles harness change for the patient’s benefit regarding cure, treatment side effects and quality of life.

Advancements in BCT are essential to improve patient outcomes, reduce side effects, and enhance overall quality of life. These advancements come in the form of changes that occur regularly based on the patient’s response to therapy, diagnostic information, emerging clinical data, evolving treatment guidelines, and changes in disease status. The team relies on evidence-based medicine to make informed decisions. They review clinical trials, research papers, and evidence-based guidelines to assess the efficacy and safety of new treatments. Continuous changes may emerge in BCT in the following aspects:

Continuous assessment and monitoring: the patient’s response to treatment is regularly monitored after the initial treatment plan is designed. Imaging tests, pathology reports, and other diagnostic tools are used to assess the effectiveness of the applied treatment approach. For example, MRI assists the oncologist by providing frequent information that influences the decision of surgical management.34–36 Adjusting dosages and treatment intensity: BCT professionals may change the amount or intensity of chemotherapy, radiation therapy, or targeted therapy based on the patient’s reaction and side effects to improve treatment outcomes while controlling adverse side effects. For example, new risk factors can be identified from low relative dose intensity (RDI) that may enhance radiotherapy treatment delivery.37 Changes may involve suggesting medium-to-high intensity physical fitness exercises to improve chemotherapy treatment completion.38 This has resulted in a lower risk of not attaining RDI.38 Another dimension in this perspective can be considered through combining different therapy approaches representing promising results in comparison with other approaches. For example, the work of combining metronomic chemo-endocrine therapy with a FulVEC regimen resulted in a high rate of clinical benefits, particularly for patients with endocrine treatment (ET) and metronomic chemotherapy (CT) resistance.39 The literature contains numerous studies concerning dose adjustment or treatment combinations recommended according to patient health characteristics and response.40,41 Incorporating new research findings: as new research and clinical trial results emerge, the treatment team may consider incorporating promising new medicines or treatment techniques into the patient’s plan, particularly if they have the potential to be more effective and safer than existing approaches. Metronomic chemo-endocrine therapy with the FulVEC regimen is a novel approach that compares favorably to other approaches in patients who are resistant to endocrine therapies.39 Similarly, clinical findings proved that medium-to-high physical fitness exercise improves chemotherapy treatment completion.38 Another finding is that radiotherapy could be reduced from about 4–6 weeks to 3 weeks for early-stage breast cancer women who have had surgery to remove a tumor with a high risk of recurrence.42 This short radiation course contributed to reducing the chance that cancer would recur in the same breast.42,43 Recently, researchers have investigated the role of artificial intelligence and deep learning in detecting BC.44,45 Innovation is becoming compulsory in the BCT field.46 For all promising research findings, researchers propose their recommendations to professionals who work in the field, where these findings could lead to changes in the form improvements for their patients’ cases. Surgical decision adjustment: the surgical approach that is part of a treatment plan may be incorporated based on the response to neoadjuvant therapies or changes in tumor size or characteristics. In recent studies, if negative margins are obtained, then multifocal and multicentric breast cancers can be surgically treated with breast-conserving surgery with no change in oncologic outcomes.47 Personalized treatment and medicine: the treatment plan may be personalized based on the patient’s unique characteristics such as age, gender, genetic factors, overall health, and preferences. Whenever BCT personalization is required, whether early or late in the BCT lifecycle, this is another means for welcoming changes. Indicating the molecular characteristics of breast cancer subtypes is necessary to create a tailored therapy and diagnosis.48 It is necessary to establish molecular profiles and metrics in order to tailor an appropriate treatment and evaluate its benefits and risks. Dose ratios and regimens are likely to change according to the identified combination therapy.49 Personalized treatment has the potential to reduce not just the treatment burden and adverse side effects but also recurrence rates. This is reported in personalized radiotherapy dosing in BCT based on genomic data instead of delivering uniform doses.50 Treatment side effect management: if the patient experiences significant adverse side effects from a treatment, the medical team may modify the treatment plan to manage these side effects effectively. Studies have reported that a large proportion of patients suffer from adjuvant ET adverse side effects, such as musculoskeletal, vulvovaginal, and vasomotor symptoms, that compromise adherence to oncological treatment outcomes and quality of life. These side effects can be mitigated through pharmacological and nonpharmacological approaches and integrated into a treatment plan.51,52 Pharmacological approaches are primary but only for short-term management without addressing the underlying causes.52,53 Exercise and psychological therapies have demonstrated potential in alleviating symptoms and providing long-term advantages.53 Recently, the effectiveness of mobile and web apps has been investigated in managing the side effects of BCTs for breast cancer survivors. Studies show that mobile apps were more frequently used and that nurses more frequently referred breast cancer survivors to mobile apps to obtain information regarding symptom management and treatment side effects.54 Addressing disease progression or recurrence: in cases where the cancer progresses or recurs, the treatment plan will be re-evaluated, and the team may incorporate changes through involving different therapies or combinations of treatments. For example, sequential single-agent chemotherapy could be designed in a treatment plan for less toxicity, but with longer treatment time. However, when there is rapid disease progression, the treatment plan is recommended to change into combination chemotherapy instead of single-agent chemotherapy.55 Studies show that combination chemotherapy resulted in significant improvement in tumor response and time for metastatic breast cancer.56 Clinical data reported a significant reduction of breast cancer recurrence when statins are integrated into the treatment plan postdiagnosis.57 Statin types and the schedule of their use according to time of diagnosis, treatment duration, follow-up timeframe, and characteristics of the patient all vary from one case to another.57 These factors can all influence changes in a BCT plan.57 Cost-effectiveness analysis: recent developments in novel BCTs have greatly improved clinical results and significantly raised the cost of treatment-related healthcare.58 Cost-effectiveness analysis is a form of systematic economic evaluation that compares health outcomes of different strategies of chemotherapy and targeted therapies in terms of cost. Cost-effectiveness evaluation depends on factors such as drug price, administration schedule, and the extent of survival rate improvement.58 The cost of cancer treatment can be a significant financial burden for patients and their families. A more cost-effective treatment option may be preferred to ensure that the patient can afford the therapy without compromising their quality of life, financial well-being, or facing severe financial strain. For example, recent studies have reported a cost-effective screening method for women with extremely dense breasts, namely, contrast-enhanced breast MRI.59 This approach is not only cost effective but has reduced breast cancer mortality for these women.59

The cancer treatment team should remain open and responsive to help the patient stay ahead of the halting of a treatment that could improve the patient’s quality of life. Changes always occur in the cancer treatment lifecycle. This principle confirms that treatment requirements or results are not always fully known or predictable. The team is required not to resist any change that is significant for the benefit of the patient. Instead, they encourage changes and implement plans for continuous improvement. Iterations of diagnosis and evaluation can be repeated for the purpose of change. BCT involves regular assessments and adjustments to the treatment plan. These changes happen based on the patient’s response to therapy, diagnostic information, emerging clinical data, evolving treatment guidelines, and changes in disease status. This principle permits for personalized modifications to optimize treatment outcomes.

In conclusion, and after validation with the domain expert, this BCT principle does fully conform, in terms of its compatibility, with the respective software engineering agile principle, but it does so in BCT terms. This leads us to classify this principle as achieving agility.

The Third Principle

In software engineering, this principle states the following: “Deliver working software frequently, from a couple of weeks to a couple of months, with a preference for a shorter timescale”.10 This principle promotes frequent incremental software delivery within a specified timeframe instead of delivering it after a long period where errors or faults are likely to happen, which may add further delay.10 Agile teams strive to allocate small timeframes to receive feedback quickly and respond to changes accordingly.10 The software should be fully functional and usable, where the customer can feel the tangible results and benefit from its use in the environment, if possible.10 This principle can be translated into BCT language as follows: “Deliver effective and safe treatment frequently with a preference for short timescales without contradicting the principles of effective and safe treatment”.

The literature reports that cancer care teams strive to deliver the required treatment within the shortest and earliest timeframes, depending on the conditions.32,42,43,60 Recent studies recommend short timeframes for radiation, especially for early-diagnosed patients.42 Therapy could be reduced from about 4–6 weeks to 3 weeks for early-stage breast cancer women who had surgery that removed a tumor with a high risk of recurrence.42 This short radiation course contributed to reducing the chance that cancer will recur in the same breast.42,43 According to experts, “This shorter course of treatment makes radiation therapy less burdensome for patients”.42 The delivery of radiation therapy for breast cancer and other malignancies is still being improved by radiation oncologists, who are also looking at ways to minimize treatment periods without sacrificing the treatment’s overall effectiveness.42,43,60 The optimal buffer of time following diagnosis is 90 days for surgery, 120 days for chemotherapy, and 365 days for radiation, if chemotherapy is administered.32 In breast cancer care guidelines, some timeframes are identified as below in:61

Within 2 weeks, a patient with symptoms and indications that might indicate breast cancer should consult a doctor. The ideal time frame for testing is 2 weeks. Within 2 weeks after the patient’s cancer diagnosis, the surgeon should ideally see them. Within 2 weeks following the initial consultation appointment, diagnostic tests should be finished. For invasive breast cancer, surgery should preferably take place 4–6 weeks following the decision to use neoadjuvant systemic therapies or within 5 weeks of the decision to treat. After deciding to treat, neoadjuvant chemotherapy should start within 4 weeks. Within 4 weeks following surgery, adjuvant chemotherapy should start for breast cancer that is HER2-positive and triple-negative. As soon as possible after chemotherapy, radiation therapy, and/or surgery is finished, endocrine therapy should commence (and in some situations, will start during neoadjuvant treatment). For patients who did not receive adjuvant chemotherapy, radiation therapy should start 3–4 weeks after chemotherapy or no later than 8 weeks following surgery.

While radiotherapy offers substantial benefits, it can also impose a time burden on breast cancer patients due to the need for multiple treatment sessions over several weeks, because of the effect that associated psychological distress and side effects have on quality of life.62 Considerable time burdens for treatment have been reported by radiotherapy patients.63 The extended treatment duration can present challenges for patients, particularly those who face geographical, financial, or transportation barriers.64,65 Moreover, workers with breast cancer experienced stress from time burdens associated with returning to work.66,67 Thus, it is crucial to consider supportive care measures that might significantly lessen side effects and the treatment timescale.63

Healthcare professionals may strike a time balance between treatment efficacy and maintaining high-quality care by putting into practice strategies like hypofractionation, APBI, telemedicine, and holistic patient support.68

To deliver more effective radiation for breast cancer and to improve the entire patient experience within the shortest timeframe, collaboration between patients, medical personnel, and researchers is crucial.

According to clinical outcomes in adjuvant endocrine therapy—a form of treatment used in hormone receptor-positive breast cancer patients after primary treatments such as surgery, chemotherapy, or radiation therapy—studies reported a disease-free survival benefit of extended endocrine therapy of 10 years versus 5 years.69

Thus, in BCT, the literature lacks an optimal uniform time frame for each modality.32 It may not always be ideal to deliver treatment within a couple of weeks or months. This timeframe varies depending on several factors that are considered for each patient’s case.32 These factors are not limited to patient circumstances and overall health, cancer type and stage, and availability of healthcare system resources. Numerous risk factors for treatment delay exist and doubling tumor times make it difficult to evaluate outcomes and impact of this long period of treatment.32 This is subjective. For example, in some cases, a treatment may not be initiated until the patient recovers from some symptoms—symptoms for which the recovery time is unknown.

In conclusion, this BCT principle does not fully conform, in terms of its compatibility, with the respective software engineering principle. This leads us to classify this principle as partially meeting agility.

The Fourth Principle

This agile software engineering principle states that “Business people and developers must work together daily throughout the project”. This principle emphasizes the significance of continuous active involvement and collaboration of both business stakeholders and developers throughout the entire software development project lifecycle. Business people are the customer’s representatives.10 They could be product owner, business analyst, manager, domain experts, or developer stakeholders who possess technician skills that are crucial for the project success.10 They include programmers, designers, architects, and testers. Their daily collaboration minimizes ambiguity, misunderstanding, risks, and delays. This principle can be translated into BCT language as follows: “Patients, their families, and treatment team must work together regularly throughout the treatment lifecycle”.

In the context of BCT, the term “regular meetings” usually refers to planned gatherings or consultations involving the patient, their healthcare team, their families if needed, and other pertinent healthcare specialists. These meetings are held periodically over the breast cancer therapy lifecycle to review the patient’s progress, discuss the treatment plan and strategies, resolve any issues, and present alternatives and decisions regarding the best course of action. For a successful BCT and management, it is essential to have collaboration and communication between patients, their families, and the treatment team.25,70 Solid collaboration ensures that everyone is informed and participating in decision-making and provides the required support throughout the treatment lifecycle. More actively engaged care partners as family members have significantly increased care benefits, showing an increase in patients’ access to portals, ability to view clinician visit notes, and understanding of illness.25,70 Herein, we present two perspectives that operationalize successful regular collaboration that are translated into the SDM and multidisciplinary (MD) approaches considering openness communication during the BCT lifecycle.

Shared decision-making: patients and their families share the decision-making responsibility with the BCT team in the treatment journey.25 Their collaboration is not necessarily daily but likely within short timeframes to provide quick feedback and act, accordingly, as discussed in the first principle. When a patient is involved in the decision-making, this permits the consideration of the patient’s preferences in the treatment and the increase in his/her satisfaction.26 The National Health Service in the UK defines the multidisciplinary team (MDT) as “a group of health and care staff who are members of different organizations and professions (eg GPs, social workers, nurses, anesthesiologist, radiologist, pathologist, etc.) that work together to make treatment and related services decisions of individual patients. MDTs are used in both health and care settings”.71 MDT individuals and their interventions can enhance the BCT planning.72–76 MDT meetings with patients also involve understanding treatment goals.25 In short, involving patients in MDT communication has enhanced and improved their quality of life and survival rate.76–80 A patient-centric process empowers BCT, and this supports addressing the agility perspective in BCT. Good, shared decisions are made based on good collaborations.26 SDM communication and collaboration start early in the breast cancer life cycle and continues after the cancer. This is seen in early diagnosis, treatment planning, treatment evaluation outcomes, managing treatment side effects, long-term management for survivorship, follow-up, palliative care, and end-of-life discussion.81 A major obstacle to SDM implementation is the lack of time and necessary training for both staff and patient.26 Regular open communication: it is crucial to maintain open regular communication, whether it is through face-to-face, email, telephone, or online channels.82 This not only involves therapeutic communication regarding sharing treatment progress, treatment strategies, changes on treatment plan, and continuous monitoring and evaluation of results. Studies have reported that women with BC communication needs were also involved in “facilitating empathy” and five associated subcategories: “trust-building therapist”, “crying out to be heard”, “seeking a soothing presence”, “sharing knowledge”, and “supportive peers”.83 This shows how providing openness and emotional support is also crucial in BCT. Tailoring psychological support for BC patients after diagnosis and treatment has demonstrated positive impact in reducing distress and depression in daily activities and patients experiencing balanced wellness.84 Communication openness implies a BCT team that does not rely exclusively on words to describe treatment risks, benefits, complications, strategies, alternatives, and side effects. Studies recommended employing other forms of communication through numbers, graphic displays, or charts.85 A recent study recommended communicating treatment risks to patients through numbers or visualizations.85 Using the effects of negative and positive framing is recommended while discussing treatment choices.85

In conclusion, at each point of communication during the BCT lifecycle, the BCT team is responsible for following an SDM approach, with openness, and using the appropriate methods of communication according to the aspect and stage in the BCT lifecycle. This is vital to enhance patient understandability in order to attain an effective participation in decision-making. However, collaboration in the BCT lifecycle does not happen daily but regularly. Hence, this leads us to classify this principle as partially meeting agility.

The Fifth Principle

The fifth agile principle states the following: “Build projects around motivated individuals. Give them the environment and support they need and trust them to get the job done”.10 This principle highlights autonomy, ownership, and accountability of team members. It is important to empower individuals and place them in the environment they require in order to excel.10 This involves accessing a positive environment atmosphere, enabling effective communication, ensuring availability of resources, having the information they need, and removing obstacles. A supportive environment is a community that encourages growth and learning. When a customer and team members are engaged, enthusiastic, and invested in their roles, they are more likely to contribute to the project.10 Trusting team members means involving them in decision-making and trusting their capabilities in carrying out their tasks without strict control. This principle can be translated into BCT language as follows: “Develop cancer treatment plans and solutions around motivated individuals. Give them the environment and support they need and trust them to get the job done”.

In this principle, we present the means for motivating individuals in terms of the patient, family, and BCT team. The motivation of BC patients is described as personal and influenced by each individual journey’s circumstances. Patient motivation evolves up and down during the BC lifecycle. However, knowing the patient’s motivation contributes to promoting their quality of life by implementing useful personalized support programs.86 Healthcare practitioners should educate women more thoroughly about breast cancer and screening services. By increasing awareness of the benefits of mobile services, mammography screening should be more widely available and accessible. In order to motivate women’s involvement in screening, national and institutional policies should be developed and implemented to address their concerns and sociocultural barriers.87

Psychological therapies frequently call for the patient’s participation and dedication. For this kind of participation, it is required that the patient be motivated.88 Therefore, prior to a patient’s participation, it is useful to analyze his/her motivations, in terms of personal goals, expectations, and needs, in order to forecast both their adherence to the intervention and the results that will be obtained.88 This facilitates useful tailoring for a targeted environment and support that they need.

Exercise is effective for reducing the burden of adverse side effects resulting from BCT. Medical oncologists should motivate survivors to engage them in performing exercises.89 The treatment team can encourage engagement in these activities through pairing enjoyment, self-monitoring, setting goals, and social support. They should also motivate survivors to exercise through using evidence-based tools and referring patients to hospital services and community activities.89 Socio-relational activities have proven to be an important source of motivation for women with cancer.88 It is recommended to focus on developing patients’ motivation and engagement in SDM by improving patients’ elicitation skills and clarification exercises of their preferences and following both formal and informal coaching approaches. The biggest barriers are lack of time and resources.26 Return to work, for women with breast cancer, can be significant and one of the biggest motivations.90 A clinical framework was developed specifically for BC patients to promote quality of life and acts as a practical guide for health professionals to help in understanding the process of returning to work based on expert consensus.90 Being around family and loved ones is another significant motivation for BC patients.

Family support is needed and can be empowered to improve the quality of BCT for patients. Patients felt motivated to undergo and recover from chemotherapy when they had received various kinds of support from their families, such as emotional, appreciation, physical, financial, instrumental, and informational support.91 There is a strong correlation between family support and a patient’s motivation to comply with chemotherapy treatment instructions.91 A family is motivated when one of its members is receiving support from other members in another family.91 Engaging a patient’s family in a BC family community group as a social network will motivate them to continue their support and social networking.92 Educating and enriching family members’ knowledge through open communication and sharing reliable information about breast cancer life cycle stages, treatment, side effects, and risks contributed to enhancing family motivation. This helps family members understand the situation and provide the appropriate kind of support required for the patient. In some countries, sociocultural values motivate and influence the role of the family to support the patient as a caregiver.93

Before the introduction of multidisciplinary care in 1995, the mortality rate was higher (11%),78 as the management complexity of BCT prevents a single specialty from covering all treatment needs for a patient. Promoting the MDT approach toward BCT is the cornerstone to enhanced treatment care outcomes for BC patients, improving their quality of life and attaining a better management outcome. The key factors that were reported to motivate MDT and address efficacy are organization structure, data availability, preparation, and meeting discipline.94 In addition, it is required to actively involve all stakeholders, such as institutions, patients, and health professionals, to develop appropriate solutions.71,78 Facilitating MDT tasks can motivate them, and this is accomplished by providing a supportive environment that enables international collaborations and operationalizes key tools such as telemedicine and electronic medical records.95 Recently, clinical decision trees have been used as a supportive tool for MDTs in their decision-making.96 MDT participation and decision-making is increased by allocating smaller caseloads, recording higher attendance at meetings, having leadership support, supportive regulations, participating in strong and continuous communication, identifying clearly involved roles and responsibilities, and considering the patient’s holistic needs.76

However, there are some barriers that constitute a challenge to addressing this principle for an MDT in its environment, including lack of financial support, lack of resources, excessive caseload, and absence of leadership.26 Patients’ physical and social barriers are additional obstacles faced by this principle.90,95

In conclusion, this BCT principle does not fully conform, in terms of its compatibility, with the respective software engineering principle. In fact, the complexity of BCT, the unpredicted outcomes, and the personalized journey of this disease do not always support providing the needed motivation and the appropriate environment. This leads us to classify this principle as partially meeting agility. However, in the optimal case, if all elements in this principle are addressed, then developing an effective and safe BCT plan is likely delivered.

The Sixth Principle

This agile principle states that “The most efficient and effective method of conveying information to and within a development team is face-to-face conversation”.10 Face-to-face communication builds stronger relationships between project members. It allows openness, real-time communication, an effective way of understanding complex ideas and solving problems, and instant feedback.10 Direct communication facilitates quick response to feedback and change.10 Body language and verbal cues enrich communication experience and skills. Global teams can simulate face-to-face communication through video conferencing tools.10 This principle can be translated into BCT language as

The most efficient and effective method of conveying information to patient and within treatment team is combination of face-to-face conversation, digital tools, and online community groups.

It is compulsory to provide a patient with all reasonable treatment options, including none.97 However, in communicating evidence, there is no correct way of communication. A picture is worth a thousand words, as they say. It conveys a lot. Thus, it is recommended to use images if there is an opportunity to reduce any bias based on emotional perspectives in decision-making.98

It is important to address patients’ needs by paying particular attention to the nonverbal aspects of communication that convey empathy and respect toward patients, as well as allowing patients to ask questions.99 Even though there are many websites dedicated to breast cancer, most of them do a poor job of providing women the crucial knowledge they need to fully engage in the decision-making process for breast cancer surgery.100 Providing patients quick access to high-quality online information has the potential to greatly enhance their decision-making experiences.100 Efficient information is conveyed through a conversation that provides benefits for patients that are revealed through real-time interaction and demonstrate emotional personalized support.

Electronic medical record (EMR) systems and electronic messages have been utilized by patients with breast cancer and contributed to improved screening behaviors and clinical benefits.101 In a recent review, the quality of life and physical health of women benefited from internet-based support treatments, but these treatments resulted in psychological distress, symptoms of anxiety and/or depression, social support, and self-efficacy.102 Online storytelling support groups were arranged to break social barriers after the end of breast cancer for women. Findings reported that the information and experience-sharing within the support group empowered these women.103,104 However, online digital tools and websites to facilitate communication between patients and healthcare providers in the cancer context are still limited.105,106 Online communities could be considered as a supplemental resource playing a significant role in filling the gap of unmet needs for breast cancer survivors.107 Online communities were used primarily during BCT for information needs and symptom management (daily or weekly) and were used less often for emotional support. Reasons provided by patients for this reduced use include lack of trust, need, and awareness.107 Patients with BC who permitted e-Health intervention reported improvement in QOL, distress, self-efficacy, and fatigue.82

Due to the specificity of BCT as reported in the literature, the appropriate information conveying approach for breast cancer patients is a combination of online resources, digital tools, and face-to-face conversations. Comparing the support received from online communities or face–face groups, patients who participated in both received the most social support.108 Patients can utilize digital tools and internet resources such as websites to educate themselves, keep updated with the latest research, and connect with international support networks that involve supporting groups.106 Patient can benefit from internet’s high availability and accessibility, a variety of valuable information and survival stories that it provides, and global networking. However, the internet is limited in terms of emotional support and personalized treatment. Regarding the face-to-face approach, patients can speak with medical staff, neighborhood support groups, and family members for individualized guidance and emotional support.

In conclusion, this BCT principle does not fully conform, in terms of its compatibility, with the respective software engineering principle. This leads us to classify this principle as partially meeting agility.

The Seventh Principle

This agile principle states that “Working software is the primary measure of progress”.10 In agile software development, real progress relies on the continuous incremental delivery of tangible outputs, that is, a working software that meets customer requirements.10 This is a priority over documentation or prototypes.10 This can be translated into BCT language as “Overall patient survival, QoL, disease free survival, and progression free survival are the ultimate measure of progress”.

Writing this principle required determining what constitutes progress in BCT. According to a BC oncologist domain expert, the following four perspectives shape the measure of progress in BCT:

Patient survival: higher survival rates are often associated with advancements in research findings, early detection, supportive care, personalized treatments, education and awareness, and long-term monitoring. Recent reports and statistics have shown that women who detected breast cancer early through national programs had a higher survival rate compared to decades ago. This is considered as progress in national and global health.109–111 Early breast cancer survivors who had a late diagnosis were more likely to have a poor quality of life because they had more unmet supportive care demands in the physical and psychological domains.112 Treatments are carried out to increase survival opportunities. Personalized treatment for breast cancer can significantly increase survival rates with tailored therapeutic approaches based on an individual patient’s preferences, specific characteristics, tumor stage, and treatment response.6,48,113 For example, it is a problem when a BC therapy lacks compliance with patient preferences and characteristics, especially in endocrine therapies. Lifestyle changes are integrated to increase the efficiency of treatment.113,114 Breast cancer education and awareness play a crucial role in increasing survival rates by promoting early detection and improving treatment outcomes.115,